Ultrasound plays an increasingly important role in the assessment and characterisation of breast lesions, especially when findings from mammography require further evaluation. While mammography remains the cornerstone of breast cancer screening, ultrasound is widely used as a highly sensitive supplemental modality to help resolve ambiguities, distinguish solid masses from cysts, guide interventions and support biopsy procedures. With its powerful image quality, advanced flow imaging and AI‑based decision support tools, LOGIQ Fortis enhances clinicians’ ability to evaluate breast anatomy with exceptional clarity and confidence.

At the heart of LOGIQ Fortis is GE HealthCare’s cSound architecture, which delivers high‑resolution images by ensuring all pixels throughout the image are in focus, from near field to depth, and supporting sensitive vascular imaging for detailed assessment of tissue perfusion. This capability is especially valuable in breast imaging, where subtle textural variances and microvascular patterns can carry critical diagnostic clues.

To support mammography‑related workflows, LOGIQ Fortis integrates AI‑based assistant tools such as the Breast Assistant powered by Koios DS. This intelligent feature helps radiologists reduce operator variability, automatically analyse lesions and provide quantitative assessments that support BI‑RADS classification, helping to focus decision‑making and potentially reduce unnecessary biopsies.

Beyond breast imaging, LOGIQ Fortis is engineered as a multi‑purpose system capable of delivering excellent performance across virtually every ultrasound application. From abdominal and liver assessments using advanced quantification tools like 2D shear wave elastography and Ultrasound‑Guided Attenuation Parameter (UGAP) to musculoskeletal, thyroid, vascular, paediatric and point‑of‑care imaging, this system adapts fluidly to the needs of diverse clinical environments.

Another key advantage of LOGIQ Fortis is its ergonomic design and workflow‑enhancing features. The intuitive EZ Imaging interface, customisable presets and streamlined touch controls reduce keystrokes and setup time, enabling clinicians of all experience levels to work efficiently even in high‑volume settings. Its mobility including battery‑powered scanning and remote operation capabilities means the system can be used at bedside, in examination rooms or in interventional suites with ease.

For departments seeking a scalable platform that supports ongoing innovation, LOGIQ Fortis also includes a robust digital ecosystem. This encompasses remote performance analytics, advanced system diagnostics, cybersecurity protection with GE’s multi‑layer SonoDefense approach and access to clinical applications and future upgrades.

In Ireland, healthcare providers now have access to LOGIQ Fortis through MDI Medical, backed by comprehensive support that includes installation, on‑site training, workflow integration and ongoing technical service. This ensures clinicians can fully leverage the system’s capabilities from the very start, helping to deliver high‑quality ultrasound across breast imaging and beyond.

The post LOGIQ Fortis – Advanced Ultrasound for Mammography and Whole‑Body Imaging, Now Available in Ireland appeared first on MDI Medical.

Invenia ABUS 2.0 has been developed specifically to address this challenge. As an advanced automated breast ultrasound solution, it provides supplemental imaging that supports the earlier detection of breast cancer in women with dense breast tissue. Clinical studies have demonstrated that when ABUS is used alongside mammography, additional cancers can be identified that would otherwise remain undetected. Importantly, many of these cancers are small, invasive and node-negative, meaning they are found at a stage where treatment options are broader and outcomes are more favourable.

Now available in Ireland from MDI Medical, Invenia ABUS 2.0 combines high-quality 3D ultrasound imaging with intelligent software designed to support radiologists in their daily practice. The system uses an operator-independent acquisition method to ensure consistent, reproducible exams, reducing variability and supporting standardised imaging across departments. The unique coronal view provides a global perspective of the breast, allowing radiologists to visualise architectural distortions and multifocal disease more clearly than with traditional handheld ultrasound alone.

The addition of AI-assisted tools further enhances diagnostic confidence by supporting lesion characterisation and streamlining image review. This can help reduce unnecessary benign biopsies while also supporting radiologists as case volumes and workload continue to grow. For healthcare providers, this means improved efficiency without compromising diagnostic quality.

Patient experience has also been a key consideration in the design of Invenia ABUS 2.0. The gently contoured transducer follows the natural shape of the breast, helping to ensure comfort and full tissue contact during the exam. The scan is non-invasive, does not involve radiation and can be completed efficiently, contributing to high patient acceptance and reassurance. Studies have shown exceptionally positive patient feedback, with women reporting a willingness to recommend ABUS screening to others.

Beyond screening, Invenia ABUS 2.0 supports the entire breast care pathway. The reproducible 3D datasets assist in diagnostic assessment, treatment planning and staging, while also enabling reliable monitoring of treatment response, including during neoadjuvant chemotherapy. By helping to detect cancer earlier and support more precise clinical decisions, ABUS can contribute to improved patient outcomes and, potentially, reduced downstream healthcare costs.

MDI Medical provides comprehensive support for Invenia ABUS 2.0 in Ireland, ensuring healthcare providers can implement the technology with confidence. This includes system installation, on-site clinical and technologist training, education programmes and ongoing technical support. With a strong focus on partnership and service, MDI Medical helps imaging teams integrate ABUS smoothly into existing workflows.

As breast imaging continues to evolve towards more personalised screening strategies, Invenia ABUS 2.0 offers a powerful solution for addressing the challenges of dense breast tissue. By combining advanced 3D ultrasound imaging, AI-enabled assistance and a strong support framework, it enables clinicians to deliver more proactive, confident and patient-centred breast care.

The post Invenia™ ABUS 2.0 with AI – Advanced Breast Imaging Available in Ireland appeared first on MDI Medical.